Gene Therapy Working Group

The EAHAD Gene Therapy Working Group was formed in 2019. The working group will strive to be at the forefront of providing critical information to physicians and patients about gene therapy in terms of practicability and safety.

Its goals are:

• To investigate gene therapy safety and its outcome parameters.
•  To provide updates on recent developments in terms of alanine aminotransferase (ALT) results and safety outcomes.
•  To collect data on the different gene therapy trials, tests, and adverse events.
•  To inform patients and medical professionals.

Discover our latest publications:

• EAHAD haemophilia gene therapy clinical
• Administration of gene therapy for haemophilia – The hub and spoke model and its regional differences and challenges outcome database (EAHAD-GTD)